13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001615982
Total reported value
$3.3B
$3.3B
37 檔
20.3%
The Q1 2025 SEC filing reveals that Venrock Adviser, LLC held a total portfolio value of $3.3B, covering 37 public equity positions.
In Q1 2025, Venrock Adviser, LLC displayed an active expansion posture, initiating 37 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including APGE, , OCUL) accounted for 20.3% of total reported equity market value during Q1 2025.
Top New Position Initiated
APGE
市值: $317.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 27.00% | +7.50% | — | |
| 2 | ✓ | Stock-Other | 8.69% | — | — | ||
| 3 | OCUL | Ocular Therapeutix Inc | Stock-Other | 7.96% | -0.19% | — | |
| 4 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.74% | -1.72% | — | |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 6.58% | -4.86% | EXIT | |
| 6 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.45% | -1.02% | — | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 4.16% | — | -3.34% | |
| 8 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.69% | +1.10% | — | |
| 9 | ORKA | Oruka Therapeutics Inc | Stock-Other | 3.62% | +4.37% | +26.26% | |
| 10 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.19% | — | — | |
| 11 | COGT | Cogent Biosciences Inc | Stock-Other | 2.90% | -0.94% | — | |
| 12 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.69% | -0.21% | — | |
| 13 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.93% | -0.01% | — | |
| 14 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.93% | — | +37.32% | |
| 15 | ✓ | Engene Holdings Inc | Stock-Other | 1.92% | -1.21% | EXIT | |
| 16 | ERAS | Erasca Inc | Stock-Other | 1.89% | +0.05% | — | |
| 17 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.51% | -0.62% | -27.58% | |
| 18 | UPB | Upstream Bio Inc | Stock-Other | 1.20% | — | — | |
| 19 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.12% | — | — | |
| 20 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.89% | +0.03% | — | |
| 21 | SLDB | Solid Biosciences Inc | Stock-Other | 0.78% | — | — | |
| 22 | SVRA | Savara Inc | Stock-Other | 0.77% | -0.05% | — | |
| 23 | ABVX | Abivax Sa-adr | Stock-Other | 0.72% | — | — | |
| 24 | ✓ | Stock-Other | 0.66% | — | — | ||
| 25 | SRZN | Surrozen Inc | Stock-Other | 0.63% | -0.19% | — | |
| 26 | ✓ | Zura Bio LTD | Stock-Other | 0.55% | -0.28% | +148.28% | |
| 27 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.41% | +0.21% | — | |
| 28 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.33% | — | -51.40% | |
| 29 | APLT | Applied Therapeutics Inc | Stock-Other | 0.23% | — | -44.27% | |
| 30 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.19% | — | -77.05% | |
| 31 | ✓ | Casi Pharmaceuticals Inc | Stock-Other | 0.18% | — | — | |
| 32 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.12% | -1.00% | EXIT | |
| 33 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.10% | — | -65.16% | |
| 34 | IPSC | Century Therapeutics Inc | Stock-Other | 0.10% | -0.08% | -36.87% | |
| 35 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.08% | — | — | |
| 36 | GLYCEUR | Glycomimetics Inc | Stock-Other | 0.05% | — | — | |
| 37 | TIL | Instil Bio Inc | Stock-Other | 0.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 2 | ✓ | — | NEW | New buy | |
| 3 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 4 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 6 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 7 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 8 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 9 | ORKA | Oruka Therapeutics Inc | — | NEW | New buy |
| 10 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 11 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 12 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 13 | DYN | Dyne Therapeutics Inc | — | NEW | New buy |
| 14 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 15 | ✓ | Engene Holdings Inc | — | NEW | New buy |
| 16 | ERAS | Erasca Inc | — | NEW | New buy |
| 17 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 18 | UPB | Upstream Bio Inc | — | NEW | New buy |
| 19 | CATBUSD | Astria Therapeutics Inc | — | NEW | New buy |
| 20 | CGEM | Cullinan Therapeutics Inc | — | NEW | New buy |
| 21 | SLDB | Solid Biosciences Inc | — | NEW | New buy |
| 22 | SVRA | Savara Inc | — | NEW | New buy |
| 23 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 24 | ✓ | — | NEW | New buy | |
| 25 | SRZN | Surrozen Inc | — | NEW | New buy |
| 26 | ✓ | Zura Bio LTD | — | NEW | New buy |
| 27 | ARTV | Artiva Biotherapeutics Inc | — | NEW | New buy |
| 28 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 29 | APLT | Applied Therapeutics Inc | — | NEW | New buy |
| 30 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 31 | ✓ | Casi Pharmaceuticals Inc | — | NEW | New buy |
| 32 | TENX | Tenax Therapeutics Inc | — | NEW | New buy |
| 33 | ✓ | Mersana Therapeutics Inc | — | NEW | New buy |
| 34 | IPSC | Century Therapeutics Inc | — | NEW | New buy |
| 35 | TNYA | Tenaya Therapeutics Inc | — | NEW | New buy |
| 36 | GLYCEUR | Glycomimetics Inc | — | NEW | New buy |
| 37 | TIL | Instil Bio Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Venrock Adviser, LLC reported a total U.S. public equity portfolio value of $3.3B across 37 disclosed positions in Q1 2025.
During Q1 2025, Venrock Adviser, LLC's top holdings by market value included APGE (27.0%)、 (8.7%)、OCUL (8.0%). The largest single position, APGE, represented 27.0% of total portfolio value.
In Q1 2025, Venrock Adviser, LLC made 37 total portfolio adjustments, initiating 37 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.